^
    Back
    Association details:
    Biomarker:IDH1 mutation
    Cancer:Oligodendroglioma
    Drug:vorasidenib (S95032) (IDH1 inhibitor, IDH2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2023
    Title:

    INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.

    Published date:
    05/25/2023
    Excerpt:
    Of the 331 pts: median age: 40.4 years (range, 16 to 71); KPS =100: 53.5%; histological subtype: oligodendroglioma: 172 and astrocytoma: 159...This is the first prospective, randomized phase 3 study of a targeted therapy in grade 2 mIDH glioma. VOR significantly improved PFS by BIRC compared with PBO with a manageable safety profile.
    DOI:
    10.1200/JCO.2023.41.17_suppl.LBA1
    Trial ID:
    INDIGO